Cinta Hierro

Badalona, CT, ES 
Badalona, CT, ES 

Overview

Cinta Hierro practices practicing medicine in Badalona, Spain.

Their clinical expertise encompasses Stomach Cancer, PIK3CA-Related Overgrowth Spectrum, Colorectal Cancer, and Cholangiocarcinoma (Bile Duct Cancer).

They are actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 2 clinical trials.

Locations

Badalona, CT, Spain
Other Locations
Barcelona, CT, Spain
Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With Metastatic Urothelial Carcinoma With FGFR 1, 2, 3, or 4 Genetic Alterations
A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With Metastatic Urothelial Carcinoma With FGFR 1, 2, 3, or 4 Genetic Alterations
Enrollment Status: Terminated
Publish Date: December 24, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

43 Total Publications

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
Journal: The New England journal of medicine
Published: May 27, 2026

Frequently Asked Questions about Cinta Hierro

Is Cinta Hierro a top-rated expert for Stomach Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Cinta Hierro is classified as an Experienced expert for Stomach Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Cinta Hierro participate in research or clinical trials?

Yes. Cinta Hierro has published 43 articles and abstracts on conditions like Stomach Cancer. You can view a list of Cinta Hierro's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hierro's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile